All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), immune chekpoint inhibitors vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.42; 0.94]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.80 [0.61; 1.05]
CheckMate 017, 2015 0.59 [0.44; 0.79]
CheckMate 057, 2015 0.73 [0.59; 0.90]
CheckMate 078, 2019 0.68 [0.52; 0.89]
JAVELIN Lung 200 (all population), 2018 0.90 [0.75; 1.08]
JAVELIN Lung 200 (PDL1 >1%), 2018 0.90 [0.72; 1.12]
OAK (all population), 2016 0.80 [0.70; 0.92]
OAK (PDL1 TC 1/2/3), 2016 0.77 [0.64; 0.92]
POPLAR, 2016 0.73 [0.53; 1.00]
0.78 [0.72 ; 0.84 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 10 12% 5,293 moderate critical deaths (OS) (extension)detailed results CheckMate 017, 2015 0.31 [0.14; 0.69]
CheckMate 078, 2019 0.75 [0.61; 0.93]
0.53 [0.22 ; 1.23 ] CheckMate 017, 2015, CheckMate 078, 2019 2 77% 776 moderate not evaluable PFS (extension)detailed results CheckMate 017, 2015 0.48 [0.24; 0.96]
CheckMate 078, 2019 0.79 [0.64; 0.97]
0.69 [0.44 ; 1.07 ] CheckMate 017, 2015, CheckMate 078, 2019 2 46% 776 moderate not evaluable progression or deaths (PFS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.71 [0.49; 1.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.77 [0.59; 1.01]
CheckMate 017, 2015 0.62 [0.47; 0.81]
CheckMate 057, 2015 0.92 [0.77; 1.10]
CheckMate 078, 2019 0.77 [0.62; 0.95]
JAVELIN Lung 200 (all population), 2018 1.16 [0.97; 1.39]
JAVELIN Lung 200 (PDL1 >1%), 2018 1.01 [0.80; 1.28]
OAK (all population), 2016 0.96 [0.85; 1.08]
OAK (PDL1 TC 1/2/3), 2016 0.87 [0.74; 1.03]
POPLAR, 2016 0.94 [0.72; 1.23]
0.88 [0.80 ; 0.98 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 10 59% 5,293 moderate low DORdetailed results OAK (PDL1 TC 1/2/3), 2016 9.61 [3.07; 30.08]
9.61 [3.07 ; 30.08 ] OAK (PDL1 TC 1/2/3), 2016 1 0% 107 NA not evaluable objective responses (ORR)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.87 [1.55; 9.69]
ARCTIC (DT ; study B ; PDL1<25%), 2020 2.43 [1.05; 5.65]
CheckMate 017, 2015 2.60 [1.26; 5.35]
CheckMate 057, 2015 1.70 [1.11; 2.61]
CheckMate 078, 2019 4.40 [1.99; 9.74]
JAVELIN Lung 200 (all population), 2018 1.40 [0.92; 2.13]
JAVELIN Lung 200 (PDL1 >1%), 2018 1.76 [1.08; 2.86]
OAK (all population), 2016 1.19 [0.85; 1.67]
OAK (PDL1 TC 1/2/3), 2016 1.41 [0.93; 2.14]
POPLAR, 2016 0.99 [0.52; 1.91]
1.73 [1.35 ; 2.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 10 51% 5,293 moderate critical objective responses (ORR) (extension)detailed results CheckMate 017, 2015 0.53 [0.19; 1.48]
CheckMate 078, 2019 4.80 [2.14; 10.77]
1.63 [0.19 ; 14.17 ] CheckMate 017, 2015, CheckMate 078, 2019 2 91% 776 moderate not evaluable AE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.24 [0.01; 5.43]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.59 [0.20; 1.69]
CheckMate 057, 2015 0.31 [0.20; 0.48]
OAK (all population), 2016 0.66 [0.39; 1.13]
POPLAR, 2016 0.87 [0.26; 2.93]
0.49 [0.31 ; 0.78 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, OAK (all population), 2016, POPLAR, 2016 5 37% 2,427 moderate not evaluable AE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.36 [0.18; 0.75]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.70 [0.43; 1.12]
CheckMate 057, 2015 0.42 [0.29; 0.59]
OAK (all population), 2016 0.51 [0.41; 0.65]
POPLAR, 2016 0.60 [0.38; 0.97]
0.51 [0.43 ; 0.60 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, OAK (all population), 2016, POPLAR, 2016 5 6% 2,427 moderate not evaluable AE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.27 [0.63; 16.86]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.41 [0.52; 3.82]
OAK (all population), 2016 0.67 [0.30; 1.53]
POPLAR, 2016 1.15 [0.34; 3.85]
1.11 [0.63 ; 1.95 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, OAK (all population), 2016, POPLAR, 2016 4 9% 1,872 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.24; 1.67]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.09 [0.58; 2.03]
OAK (all population), 2016 0.58 [0.45; 0.75]
POPLAR, 2016 0.29 [0.14; 0.61]
0.60 [0.38 ; 0.94 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, OAK (all population), 2016, POPLAR, 2016 4 58% 1,872 moderate not evaluable SAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.73 [0.81; 3.73]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.76 [1.04; 2.99]
POPLAR, 2016 1.05 [0.64; 1.73]
1.41 [0.99 ; 2.01 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, POPLAR, 2016 3 13% 685 moderate not evaluable SAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.03; 0.33]
OAK (all population), 2016 1.03 [0.80; 1.31]
0.34 [0.03 ; 3.42 ] CheckMate 017, 2015, OAK (all population), 2016 2 93% 1,447 moderate not evaluable STRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.33; 3.10]
CheckMate 017, 2015 0.23 [0.11; 0.51]
CheckMate 057, 2015 0.32 [0.19; 0.55]
CheckMate 078, 2019 0.59 [0.34; 1.02]
JAVELIN Lung 200 (all population), 2018 0.37 [0.24; 0.57]
0.41 [0.28 ; 0.59 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 5 44% 2,191 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 057, 2015 0.25 [0.14; 0.46]
CheckMate 078, 2019 0.34 [0.18; 0.66]
0.29 [0.19 ; 0.45 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable TRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.19 [0.08; 0.46]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.39 [0.22; 0.69]
CheckMate 017, 2015 0.22 [0.12; 0.41]
CheckMate 078, 2019 0.35 [0.22; 0.57]
JAVELIN Lung 200 (all population), 2018 0.29 [0.21; 0.42]
OAK (all population), 2016 0.29 [0.22; 0.39]
POPLAR, 2016 0.27 [0.15; 0.51]
0.30 [0.25 ; 0.35 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 7 0% 3,383 moderate not evaluable TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.13 [0.05; 0.36]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.49 [0.29; 0.84]
CheckMate 017, 2015 0.06 [0.03; 0.13]
CheckMate 057, 2015 0.10 [0.06; 0.16]
CheckMate 078, 2019 0.15 [0.10; 0.24]
JAVELIN Lung 200 (all population), 2018 0.12 [0.08; 0.18]
OAK (all population), 2016 0.23 [0.18; 0.31]
POPLAR, 2016 0.20 [0.11; 0.38]
0.16 [0.11 ; 0.24 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 8 81% 3,938 moderate not evaluable TRAE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 078, 2019 0.61 [0.14; 2.77]
JAVELIN Lung 200 (all population), 2018 0.19 [0.05; 0.68]
OAK (all population), 2016 0.47 [0.02; 14.16]
POPLAR, 2016 0.31 [0.03; 3.04]
0.33 [0.15 ; 0.72 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 7 0% 3,383 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.24; 4.26]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.81 [0.81; 4.05]
CheckMate 017, 2015 0.28 [0.09; 0.89]
CheckMate 078, 2019 0.66 [0.32; 1.37]
JAVELIN Lung 200 (all population), 2018 0.47 [0.29; 0.77]
POPLAR, 2016 0.07 [0.02; 0.29]
0.52 [0.25 ; 1.06 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, POPLAR, 2016 6 74% 2,196 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 017, 2015 0.23 [0.05; 1.13]
CheckMate 078, 2019 0.80 [0.33; 1.95]
0.52 [0.16 ; 1.64 ] CheckMate 017, 2015, CheckMate 078, 2019 2 44% 753 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
1.06 [0.20 ; 5.55 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 5 0% 2,214 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
1.69 [0.24 ; 12.08 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, JAVELIN Lung 200 (all population), 2018 3 0% 1,166 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.65 [0.10 ; 4.29 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,066 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.21 [0.02; 2.02]
CheckMate 017, 2015 0.12 [0.01; 2.29]
CheckMate 057, 2015 0.13 [0.02; 1.07]
CheckMate 078, 2019 0.15 [0.02; 1.47]
JAVELIN Lung 200 (all population), 2018 0.03 [0.00; 0.44]
0.11 [0.04 ; 0.31 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 6 0% 2,474 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.72 [0.08 ; 6.15 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 017, 2015 0.10 [0.01; 1.76]
CheckMate 057, 2015 0.15 [0.02; 1.28]
JAVELIN Lung 200 (all population), 2018 0.06 [0.01; 0.49]
0.15 [0.05 ; 0.46 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 5 0% 1,981 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Colitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 3.86 [0.19; 77.90]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
2.18 [0.49 ; 9.65 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 5 0% 2,214 moderate serious Constipation TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.23 [0.01; 5.17]
0.44 [0.06 ; 3.16 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 057, 2015 3 0% 940 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.09; 4.55]
CheckMate 017, 2015 0.98 [0.06; 15.91]
CheckMate 057, 2015 0.15 [0.01; 3.09]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.07 [0.00; 1.15]
0.37 [0.12 ; 1.15 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 6 0% 2,474 moderate not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 3.24 [0.37; 28.15]
CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 057, 2015 0.62 [0.10; 3.74]
CheckMate 078, 2019 0.93 [0.03; 27.74]
JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
0.68 [0.24 ; 1.94 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 6 0% 2,474 moderate not evaluable Dizziness TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33]
JAVELIN Lung 200 (all population), 2018 0.46 [0.04; 5.13]
0.88 [0.13 ; 5.89 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, JAVELIN Lung 200 (all population), 2018 2 0% 1,041 moderate not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.47 [0.10; 2.13]
CheckMate 017, 2015 0.09 [0.01; 0.73]
CheckMate 057, 2015 0.21 [0.06; 0.74]
CheckMate 078, 2019 0.27 [0.06; 1.15]
JAVELIN Lung 200 (all population), 2018 0.09 [0.01; 0.71]
0.23 [0.11 ; 0.46 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 6 0% 2,474 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
CheckMate 017, 2015 0.03 [0.00; 0.58]
CheckMate 057, 2015 0.02 [0.00; 0.27]
JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.20]
0.03 [0.01 ; 0.11 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 4 0% 1,698 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.93 [0.03; 27.74]
0.93 [0.03 ; 27.74 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Headache TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.92 [0.20; 18.73]
1.96 [0.30 ; 13.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020 2 0% 408 moderate not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 1.39 [0.14; 13.49]
1.39 [0.14 ; 13.49 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.23 [0.01; 6.90]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.58 [0.10 ; 3.35 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,089 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.11; 14.23]
JAVELIN Lung 200 (all population), 2018 1.86 [0.17; 20.62]
1.54 [0.28 ; 8.47 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, JAVELIN Lung 200 (all population), 2018 2 0% 1,041 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.73 [0.10 ; 5.17 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019 4 0% 1,456 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
0.92 [0.17 ; 5.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 5 0% 2,214 moderate serious Increase AST TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.03; 7.42]
0.76 [0.12 ; 5.04 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,331 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.04; 10.24]
CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.03; 7.42]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
0.82 [0.18 ; 3.65 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,089 moderate not evaluable Increased lacrimation (TRAE grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
JAVELIN Lung 200 (all population), 2018 3.74 [0.42; 33.65]
2.35 [0.44 ; 12.50 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, JAVELIN Lung 200 (all population), 2018 3 0% 1,166 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 5.64 [0.68; 47.10]
1.61 [0.39 ; 6.60 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 5 0% 2,214 moderate serious Leucopenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.16 [0.01; 3.32]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.10 [0.01; 2.08]
CheckMate 017, 2015 0.19 [0.02; 1.66]
CheckMate 057, 2015 0.02 [0.00; 0.32]
CheckMate 078, 2019 0.02 [0.00; 0.18]
JAVELIN Lung 200 (all population), 2018 0.05 [0.00; 0.78]
0.06 [0.02 ; 0.17 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 6 0% 2,474 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.09 [0.00; 1.69]
JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
0.17 [0.03 ; 1.05 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 1.87 [0.06; 55.99]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.55 [0.08 ; 3.90 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.93 [0.02 ; 46.93 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Myositis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Nausea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 057, 2015 0.93 [0.13; 6.67]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.43 [0.12 ; 1.49 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 5 0% 1,981 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.09 [0.01; 1.76]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.03 [0.00; 0.45]
CheckMate 017, 2015 0.01 [0.00; 0.15]
CheckMate 057, 2015 0.00 [0.00; 0.08]
CheckMate 078, 2019 0.03 [0.01; 0.15]
JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.13]
0.02 [0.01 ; 0.06 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 6 0% 2,474 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.63 [0.05 ; 8.17 ] CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 2 0% 1,313 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33]
2.56 [0.11 ; 57.33 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.96 [0.06 ; 15.39 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 057, 2015 0.15 [0.01; 3.09]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.16 [0.03 ; 0.88 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.47 [0.02; 13.95]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.48 [0.09 ; 2.62 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 4 0% 1,856 moderate not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
JAVELIN Lung 200 (all population), 2018 0.09 [0.00; 1.68]
0.37 [0.06 ; 2.22 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, JAVELIN Lung 200 (all population), 2018 3 0% 1,166 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
ARCTIC (DT ; study B ; PDL1<25%), 2020 6.52 [0.35; 120.50]
CheckMate 017, 2015 1.98 [0.07; 59.45]
CheckMate 057, 2015 2.82 [0.29; 27.28]
CheckMate 078, 2019 3.74 [0.20; 71.10]
JAVELIN Lung 200 (all population), 2018 2.80 [0.29; 27.04]
2.94 [0.94 ; 9.18 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 6 0% 2,474 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 057, 2015 0.93 [0.02; 47.22]
1.11 [0.09 ; 14.57 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015 2 0% 838 moderate not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.65 [0.07 ; 6.26 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,331 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50]
CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.57 [0.09 ; 3.51 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 4 0% 1,856 moderate not evaluable Rash TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
ARCTIC (DT ; study B ; PDL1<25%), 2020 0.31 [0.03; 3.50]
CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 2.79 [0.14; 56.11]
0.75 [0.21 ; 2.72 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 5 0% 1,716 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 6.60 [0.37; 116.99]
6.60 [0.37 ; 116.99 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Sepsis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.23 [0.01; 5.14]
0.23 [0.01 ; 5.14 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 2.79 [0.14; 56.11]
2.79 [0.14 ; 56.11 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 057, 2015 0.23 [0.01; 5.17]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.49 [0.10 ; 2.44 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 4 0% 1,721 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.16 [0.01; 3.50]
0.16 [0.01 ; 3.50 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.65 [0.07 ; 6.26 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,331 moderate not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Vomiting TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50]
CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.34 [0.06 ; 1.86 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 4 0% 1,856 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
JAVELIN Lung 200 (all population), 2018 0.93 [0.06; 14.90]
1.05 [0.12 ; 9.05 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, JAVELIN Lung 200 (all population), 2018 2 0% 1,041 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results CheckMate 057, 2015 0.15 [0.01; 3.09]
0.15 [0.01 ; 3.09 ] CheckMate 057, 2015 1 0% 555 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 03:13 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743